Patents Assigned to Biogen Idec Ma Inc.
  • METHODS FOR USE WITH BAFF ANTAGONISTS
    Publication number: 20140213470
    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., BIOGEN IDEC MA INC.
    Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
  • Bruton's tyrosine kinase inhibitors
    Patent number: 8785440
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: July 22, 2014
    Assignees: Biogen Idec MA, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
    Patent number: 8784823
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: July 22, 2014
    Assignees: Biogen Idec MA Inc., UCB Biopharma SPRL
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Method for delivering interferon-?
    Patent number: 8784399
    Abstract: The method described herein reduces the amount of aggregating metal released into solutions of Interferon-?.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: July 22, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Eric Anthony Faulkner, Mary Diana DiBiase
  • Sp35 Antibodies and Uses Thereof
    Publication number: 20140199315
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: November 12, 2013
    Publication date: July 17, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff
  • Process for Preparing High Purity and Crystalline Dimethyl Fumarate
    Publication number: 20140200363
    Abstract: The present invention describes a process for the preparation of dimethyl fumarate. The process involves the esterification of fumaric acid and methanol in the presence of sulfuric acid as an acid catalyst. The high purity dimethyl fumarate contains no more than trace amounts of dimethyl sulfate. The present invention also provides a process for the preparation of highly pure dimethyl fumarate with a particle size from 20 to 250???.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 17, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: John Guzowski, William Kiesman, Erwin Irdam
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
    Publication number: 20140199291
    Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
    Type: Application
    Filed: September 13, 2008
    Publication date: July 17, 2014
    Applicant: Biogen Idec MA Inc
    Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
  • Deuterium Substituted Fumarate Derivatives
    Publication number: 20140194427
    Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 10, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventor: Jianhua CHAO
  • SPECTROSCOPIC ANALYSIS OF NUTRIENT MATERIALS FOR USE IN A CELL CULTURE PROCESS
    Publication number: 20140185033
    Abstract: In some embodiments, aspects of the disclosure relate to methods of evaluating cell culture materials, for example, nutrient materials, or other materials that can be used in cell culture media.
    Type: Application
    Filed: December 11, 2013
    Publication date: July 3, 2014
    Applicant: Biogen Idec MA Inc.
    Inventor: Justin Moretto
  • NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES
    Publication number: 20140187485
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Application
    Filed: August 2, 2013
    Publication date: July 3, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Christine M. Ambrose, Jeffrey S. Thompson
  • NOGO receptor binding protein
    Patent number: 8765662
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: July 1, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, John McCoy, R. Blake Pepinsky, Daniel H. S. Lee
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140178382
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: April 16, 2013
    Publication date: June 26, 2014
    Applicant: Biogen IDEC MA, Inc.
    Inventors: ANTONIN R. DE FOUGEROLLES, VICTOR E. KOTELIANSKI, CARL REID, ELLEN GARBER
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20140161794
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: April 15, 2011
    Publication date: June 12, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Alexey Lugovskoy, Frederick R. Taylor, Karen Retta McLachlan
  • Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
    Publication number: 20140163100
    Abstract: Methods of treating multiple sclerosis in a subject, including: reducing the frequency of relapse, reducing the annualized relapse rate, reducing the risk of disability progression, reducing the number of new or newly enlarging T2 lesions, reducing the number of gadolinium lesions; and methods of preserving/increasing myelin content in a subject having multiple sclerosis; by daily administering a composition containing a fumarate, such as dimethyl fumarate or monomethyl fumarate, to the subject.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: Katherine Dawson, Gilmore O'Neill, Alfred Sandrock
  • METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20140154259
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: September 9, 2013
    Publication date: June 5, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: ANTONIN DE FOUGEROLLES, Philip Gotwals, Roy R. Lobb, Victor E. Kotelianski
  • Light targeting molecules and uses thereof
    Patent number: 8734795
    Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: May 27, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Xinzhong Wang, Veronique Bailly, Alexey Lugovskoy, Graham K. Farrington, Christilyn Graff, Scott Glaser
  • Methods for treating inflammatory bowel disease
    Patent number: 8728475
    Abstract: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-? are disclosed, as are other methods.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 20, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Timothy Zheng
  • Refolding transforming growth factor beta family proteins
    Patent number: 8722862
    Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: May 13, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
  • Medicament delivery device
    Patent number: D707352
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: June 17, 2014
    Assignee: Biogen IDEC MA Inc.
    Inventors: Roger W. Liu, Ping Y. Yeh, Lucio Giambattista
  • Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants
    Patent number: RE44962
    Abstract: The invention relates to a DNA fragment containing a determined gene, the expression of which inhibits the antibiotic and herbicidal effects of Bialaphos and related products. It also relates to recombinant vectors, containing such DNA fragment, which enable this protective gene to be introduced and expressed into cells and plant cells.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: June 24, 2014
    Assignees: Bayer Cropscience N.V., Biogen Idec MA Inc.
    Inventors: Jan Leemans, Johan Botterman, Marc De Block, Charles Thompson, Rao Mouva